Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 5003

BillFederalHouseIn Committee
Safe Medicine Act
About This Bill
Committee
Latest Action · September 9, 2021
Referred to the Subcommittee on Oversight and Investigations.
Congress
117th (2021–2023)
Introduced
August 10, 2021
Cosponsors (1)
1D 0R
View PDF ↗

Summary

Highlight any text to annotate
Safe Medicine Act This bill addresses issues related to the manufacture of drugs, including essential medicines. The Department of Health and Human Services, the Department of Defense, and the Department of Veterans Affairs must jointly develop and implement a strategy to increase the domestic production of essential medicines, medical countermeasures, and critical inputs. If the Food and Drug Administration determines that a drug or active pharmaceutical ingredient is manufactured in a country that may be producing contaminated drugs or ingredients due to systemic manufacturing-related problems, the labeling for that drug or ingredient must have a boxed warning about the potential for contamination. For government procurement purposes, the President's authority to waive certain purchasing requirements that discriminate against foreign products may not be used to waive any preferences for goods that are essential medicines, medical countermeasures, or critical inputs.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.